BACKGROUND Recent studies have cast doubt on the benefit of cardiac resynchronization therapy (CRT) with defibrillation (CRT-D) versus pacing (CRT-P) for patients with nonischemic cardiomyopathy (NICM). Left ventricular myocardial scar portends poor clinical outcomes.
C ardiac resynchronization therapy (CRT) is a standard treatment for patients with heart failure (HF), impaired left ventricular (LV) systolic function, and a prolonged QRS duration (1, 2) . Although CRT-pacing (CRT-P) prevents pump failure by correcting LV dyssynchrony, the addition of defibrillation (CRT-D) leads to a greater treatment effect by preventing sudden cardiac death (SCD) from ventricular arrhythmias (2, 3) .
It is well recognized that the clinical outcome of CRT is influenced by the underlying etiology of HF.
Nonischemic cardiomyopathy (NICM) is associated with a better LV reverse remodeling response (4) and better clinical outcomes after CRT (5) . Because NICM is associated with a lower background risk for ventricular arrhythmias than ischemic cardiomyopathy, the benefit of CRT-D over CRT-P has been questioned.
In this respect, most of the evidence in favor of defibrillation in patients with NICM comes from studies evaluating patients with single-or dualchamber implantable cardioverter-defibrillators (ICD) rather than CRT-D devices. Both CAT (Cardiomyopathy Trial) (6) and AMIOVIRT (Amiodarone Versus Implantable Cardioverter-Defibrillator Trial) (7) used single-and dual-chamber ICDs, but neither trial showed any survival benefit from ICDs in patients with NICM. Importantly, these studies involved small numbers of patients (each about 100).
In the DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation) study (8) , in which 458 patients with NICM were randomized to medical therapy or a single-chamber ICD, ICD therapy did not reduce total mortality, despite a significant reduction in SCD. A subgroup analysis of SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial),
including patients with NICM, also failed to show a significant reduction in mortality from ICD therapy (9) . In the recent DANISH (Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure) study, ICDs did not reduce total mortality in patients with NICM (10) . These studies cast doubt on the relative benefit of CRT-D versus CRT-P in patients with NICM.
All clinical outcome studies of ICDs in NICM (6) (7) (8) (9) 11) , including DANISH (10) , have defined NICM on the basis of findings from echocardiography, coronary angiography, and/or nuclear imaging. These imaging modalities, however, do not provide tissue characterization. In this regard, LV midwall fibrosis (MWF) is a specific form of myocardial scar found in approximately 30% of patients with NICM ( Figure 1) .
It is now recognized that MWF, detected using cardiac magnetic resonance (CMR) imaging, portends a poor outcome in the general NICM population (12) (13) (14) (15) and in CRT-P recipients (16) . Increasing evidence supports a link between MWF and ventricular arrhythmias (12) (13) (14) 17) . On this basis, we hypothesized that the relative benefit of CRT-D over CRT-P is influenced by MWF.
METHODS

Patients were recruited from 2 centers (Good Hope
Hospital and Queen Elizabeth Hospital, Birmingham, United Kingdom). All patients underwent successful CRT device implantation and pre-implantation CMR from July 2002 to January 2017. Some patients were included in a previous study (16) .
The present study extended to a larger group and a longer follow-up period. (19) . As in other studies (12, 14, 16, 17, 20) , we chose to use visual rather than quantitative assessment of MWF to make our findings clinically applicable without the need for scar quantification. 
RESULTS
In the total study population (n ¼ 252), 68 patients Table 2 .
In multivariate analyses ( Total mortality or HF hospitalization was 34 of 68 (50%) in þMWF and 76 of 184 (41.3%) in ÀMWF, amounting to annualized rates of 16.9% for þMWF and 9.2% for ÀMWF. In Kaplan-Meier survival analyses, þMWF was associated with higher total mortality or HF hospitalization (log-rank p ¼ 0.005) ( Figure 2) . In multivariate analyses, þMWF was associated with higher total mortality or HF hospitalization (aHR: 2.02; 95% CI: 1.32 to 3.09), independent of age, NYHA functional class, hypertension, and left bundle branch block. Other potential confounders did not reach significance in multivariate models.
Total mortality or hospitalization for MACE was 35 of 68 (51%) in þMWF and 81 of 184 (44%) in ÀMWF, amounting to annualized rates of 17.6% for þMWF and 9.9% for ÀMWF. In Kaplan-Meier survival analyses, þMWF was associated with lower survival (log-rank p ¼ 0.009) ( Figure 2) . In multivariate analyses, þMWF was associated with higher total mortality or hospitalization for MACE (aHR: 2.02; 95% CI: 1.32 to 3.07), independent of age, NYHA class, CRT type, and diabetes. Other potential confounders did not reach significance in multivariate models.
With respect to mode of death, this was unknown in 1 patient who underwent CRT-P (ÀMWF).
Excluding this patient, þMWF was associated with a higher mortality from pump failure (aHR: 1.95; 95% CI: 1.11 to 3.41) (Figure 3 , Online Table 1 ). As shown in 
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The presence of midwall fibrosis (MWF) was associated with higher total mortality as well as hospitalization for heart failure (HF) and major adverse cardiac events (MACEs). ventricular arrhythmias (aHR: 2.60; 95% CI: 1.02 to 6.63) were also higher in þMWF (Online Table 1 ).
MWF AND DEVICE TYPE. In univariate ( Table 2 ) and multivariate ( to 0.78) than CRT-P in þMWF, but not in ÀMWF.
Event rates are shown in Table 4 . Similarly, cardiac mortality in the present study (39.7% in þMWF and 23.4% in ÀMWF) was also higher than in DANISH ("cardiovascular mortality" of 13.8% in the ICD group and 17% in the control group).
It would appear, therefore, that compared with patients in DANISH, patients in the present study were "sicker," and a greater proportion died from cardiac causes.
In separate analyses of þMWF and ÀMWF, CRT-D was superior to CRT-P in NICM þMWF. Even though patient numbers were approximately 3 times higher in the ÀMWF subgroup, no differences in outcomes emerged between CRT-D and CRT-P. Admittedly, total mortality was lower in ÀMWF than in þMWF (annualized rate of 6.9 vs. 12.8), raising the possibility that larger numbers might be needed to show a benefit from CRT-D over CRT-P in NICM ÀMWF.
Notwithstanding, our findings suggested that MWF identifies a subpopulation of patients with NICM who are more likely to benefit from CRT-D.
Our finding of a higher risk for pump failure deaths and HF hospitalizations in þMWF was not unexpected. We have previously shown that MWF is associated with a selective impairment of circumferential LV myocardial strain, apical rotation, and diastolic function (27). The result is a "stiff" left ventricle, which is less able to twist to an applied torque (rotation) and more likely to move as a solid body. These mechanical disturbances may be responsible for the known associations of MWF with HF and the suboptimal response to medical and device therapy (12) (13) (14) 16, 17) .
In the present study, we found that compared with ÀMWF, þMWF was associated with a 3.75-fold higher risk for SCD and a 2. provide continuous re-entry. Clinical studies have also shown that MWF is associated with an increased risk for ventricular arrhythmias (12) (13) (14) 17) . Other studies supported the use of T1 mapping in predicting ventricular arrhythmias in ICD recipients (29).
Physicians may refer to the DANISH study as a basis for making decisions on the choice of device therapy in patients with NICM. We should consider, however, that DANISH did not use CMR for tissue characterization of the underlying cardiomyopathy.
In the present study, we showed that NICM with MWF behaves differently than NICM without MWF.
On this basis, MWF should be regarded as a "high- Values are %. *Data are expressed in terms of annualized event rates. Tables 1 and 2 
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